New research has identified a strategy to make #AntibodyDrugConjugates more effective against #metastatic #CastrationResistant #ProstateCancer, potentially overcoming #TreatmentResistance.
#ProstateCancerTreatment #CombinationTherapy
#ProstateCancerTreatment #CombinationTherapy
Combination of targeted therapies could help overcome treatment resistance in advanced prostate cancer – BioNews Central
New research has identified a strategy to make antibody-drug conjugates more effective against metastatic castration-resistant prostate cancer, potentially overcoming treatment resistance. ...
sbee.link
August 3, 2026 at 9:05 PM
New research has identified a strategy to make #AntibodyDrugConjugates more effective against #metastatic #CastrationResistant #ProstateCancer, potentially overcoming #TreatmentResistance.
#ProstateCancerTreatment #CombinationTherapy
#ProstateCancerTreatment #CombinationTherapy
Researchers identify CDC20, DTL, & RRM2 as #AR‑independent drivers of advanced #ProstateCancer via RB1/E2F1, with novel inhibitors surpassing AR antagonists, offering new #CastrationResistant targets & a #bioinformatics‑driven discovery paradigm.
#OpenAccess: doi.org/10.1016/j.ge...
#OpenAccess: doi.org/10.1016/j.ge...
January 5, 2026 at 1:37 AM
Researchers identify CDC20, DTL, & RRM2 as #AR‑independent drivers of advanced #ProstateCancer via RB1/E2F1, with novel inhibitors surpassing AR antagonists, offering new #CastrationResistant targets & a #bioinformatics‑driven discovery paradigm.
#OpenAccess: doi.org/10.1016/j.ge...
#OpenAccess: doi.org/10.1016/j.ge...
This review highlights how #ferroptosis—offers promise for #CastrationResistant #ProstateCancer, outlining its regulatory networks, emerging combination strategies, #biomarker-driven precision approaches, and hurdles to clinical translation.
#OpenAccess: doi.org/10.1016/j.ge...
#OpenAccess: doi.org/10.1016/j.ge...
December 12, 2025 at 1:04 PM
This review highlights how #ferroptosis—offers promise for #CastrationResistant #ProstateCancer, outlining its regulatory networks, emerging combination strategies, #biomarker-driven precision approaches, and hurdles to clinical translation.
#OpenAccess: doi.org/10.1016/j.ge...
#OpenAccess: doi.org/10.1016/j.ge...
March is #ProstateCancerAwarenessMonth in the UK📣
Omid Yazdanpanah, MD explores the potential of #radioligandtherapy combined with #androgen receptor pathway inhibitors (ARPIs) for #metastatic #castrationresistant #prostatecancer (mCRPC)🔬
👉 buff.ly/q8aQ75D
Omid Yazdanpanah, MD explores the potential of #radioligandtherapy combined with #androgen receptor pathway inhibitors (ARPIs) for #metastatic #castrationresistant #prostatecancer (mCRPC)🔬
👉 buff.ly/q8aQ75D
March 27, 2025 at 9:01 AM
March is #ProstateCancerAwarenessMonth in the UK📣
Omid Yazdanpanah, MD explores the potential of #radioligandtherapy combined with #androgen receptor pathway inhibitors (ARPIs) for #metastatic #castrationresistant #prostatecancer (mCRPC)🔬
👉 buff.ly/q8aQ75D
Omid Yazdanpanah, MD explores the potential of #radioligandtherapy combined with #androgen receptor pathway inhibitors (ARPIs) for #metastatic #castrationresistant #prostatecancer (mCRPC)🔬
👉 buff.ly/q8aQ75D
#Research
Histone methyltransferase KMT2D targets the SPOP-G3BP1 axis to enhance AR stability and drive castration-resistant prostate cancer progression doi.org/10.1186/s435...
#AndrogenReceptor #CastrationResistant #Methylation #Signaling #Ubiquitination
Histone methyltransferase KMT2D targets the SPOP-G3BP1 axis to enhance AR stability and drive castration-resistant prostate cancer progression doi.org/10.1186/s435...
#AndrogenReceptor #CastrationResistant #Methylation #Signaling #Ubiquitination
Histone methyltransferase KMT2D targets the SPOP-G3BP1 axis to enhance AR stability and drive castration-resistant prostate cancer progression - Molecular Biomedicine
Castration-resistant prostate cancer (CRPC) poses a significant clinical challenge, characterized by limited therapeutic options and unfavorable prognosis, particularly among elderly men. Reactivation...
doi.org
December 5, 2025 at 2:16 AM
#Research
Histone methyltransferase KMT2D targets the SPOP-G3BP1 axis to enhance AR stability and drive castration-resistant prostate cancer progression doi.org/10.1186/s435...
#AndrogenReceptor #CastrationResistant #Methylation #Signaling #Ubiquitination
Histone methyltransferase KMT2D targets the SPOP-G3BP1 axis to enhance AR stability and drive castration-resistant prostate cancer progression doi.org/10.1186/s435...
#AndrogenReceptor #CastrationResistant #Methylation #Signaling #Ubiquitination